Faheem Hasnain on stage at the Endpoints News / PharmCube #BIIS18 summit in Shanghai (Endpoints News)
April 25, 2022 09:07 AM EDT
R&D

Fa­heem Has­nain ac­knowl­edges an­oth­er set­back for the Gos­samer pipeline, but in­vestors aren't pan­ick­ing

John Carroll

Editor & Founder

Fa­heem Has­nain’s at­tempt to break new ground in treat­ing ul­cer­a­tive col­i­tis at Gos­samer Bio has bro­ken down at the Phase II fin­ish line.

The biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bi­cy­cle Ther­a­peu­tics stock sinks fol­low­ing re­lease of topline da­ta, post-hoc analy­ses

Ab­b­Vie makes an­oth­er small I&I ac­qui­si­tion, buy­ing Nim­ble for $200M

EMA's com­mit­tee says ex­pand­ed la­bel for Lil­ly's Moun­jaro in­to sleep ap­nea not nec­es­sary

McK­in­sey hit with a $650M fine for de­ceiv­ing US about opi­oid con­sult­ing work

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times